Bacteremia clinical trials at UCSD
1 research study open to eligible people
open to eligible people ages 18 years and up
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to Best Available Antibiotic Therapy Alone for the Treatment of Adults With Bacteremia Due to Staphylococcus aureus
La Jolla, California and other locations
Our lead scientists for Bacteremia research studies include Saima Aslam, MD.